Comparison of two kits of anti-infliximab antibodies plasmatic measurement | Zendy

Rim Charfi | Zendy; Ines Mahmoud | Zendy; Fatma Ben Salem | Zendy; Myriam Moalla | Zendy; Salma Bouden | Zendy; Imen Sfar | Zendy; O. Saidane | Zendy; Anis Klouz | Zendy; Riadh Daghfous | Zendy; Yousr Gorgi | Zendy; L. Abdelmoula | Zendy; Sameh Trabelsi | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Comparison of two kits of anti-infliximab antibodies plasmatic measurement

Author(s) -

Rim Charfi,

Ines Mahmoud,

Fatma Ben Salem,

Myriam Moalla,

Salma Bouden,

Imen Sfar,

O. Saidane,

Anis Klouz,

Riadh Daghfous,

Yousr Gorgi,

L. Abdelmoula,

Sameh Trabelsi

Publication year - 2019

Publication title -

annales de biologie clinique

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.167

H-Index - 27

eISSN - 1950-6112

pISSN - 0003-3898

DOI - 10.1684/abc.2019.1454

Subject(s) - medicine , gynecology

Infliximab (IFX) is a chimeric monoclonal antibody which has proven its efficacy in the treatment of inflammatory diseases. However, its efficacy can be limited by the development of anti-IFX antibodies (ATI) resulting in a therapeutic failure of IFX. ATI plasmatic monitoring is then indicated to optimize IFX treatment. The aim of this study was to validate an ELISA (enzyme linked immuno sorbent assay) method of ATI plasmatic monitoring.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research